In this report we describe the cloning and characterization of ADA5, a gene identified by resistance to GAL4-VP16-mediated toxicity. ADA5 binds directly to the VP16 activation domain but not to a transcriptionally defective VP16 double point mutant. Double mutants with mutations in ada5 and other genes (ada2 or ada3) isolated by resistance to GAL4-VP16 grow like ada5 single mutants, suggesting that ADA5 is in the same pathway as the other ADA genes. Further, ADA5 cofractionates and coprecipitates with ADA3. However, an ada5 deletion mutant exhibits a broader spectrum of phenotypes than mutants with null mutations in the other ADA genes. Most interestingly, ADA5 is identical to SPT20 (S. M. Roberts and F. Winston, Mol. Cell. Biol. 16: 3206-3213, 1996), showing that it shares phenotypes with the ADA and SPT family of genes. Of the other SPT genes tested, mutants with mutations in SPT7 and, strikingly, SPT15 (encoding the TATA-binding protein) show resistance to GAL4-VP16. We present a speculative pathway of transcriptional activation involving the ADA2-ADA3-GCN5-ADA5 complex and the TATA-binding protein.
In eukaryotes, transcriptional activation is a central means of gene regulation. RNA polymerase II, which is responsible for transcribing mRNA, is recruited to transcriptional start sites via its interaction with the general transcription factors. These factors recognize the TATA box or initiator elements found near the start site. Moreover, transcriptional activators, which bind enhancer/UAS elements found hundreds of base pairs away from the TATA box, can greatly stimulate the initiation of transcription. These transcriptional activators are often modular in structure; one domain is responsible for recognizing the DNA, and another domain is responsible for transcriptional activation (18) . The mechanism by which these activation domains function remains unknown, although it is the focus of much research.
It is clear that proteins other than the general transcription factors and activators are necessary for activated transcription (41) . These factors, termed coactivators or adapters, have been identified by using various genetic and biochemical methods and are thought to function by mediating the interaction between basal factors and activation domains (3, 31, 41) . TFIID, a complex of the TATA-binding protein (TBP) and TBP-associated factors (TAFs), is capable of supporting activated transcription, whereas TBP alone cannot (9) . Further, different TAF subunits bind to and mediate activation by different classes of activation domains (17, 28, 48, 56) . Additionally, other, non-TAF coactivators identified in metazoans or their viruses include PC4/p15 (15, 35) , CBP (36) , and the X protein from hepatitis B virus (24) . These proteins have been shown to have the properties expected of coactivators, including the ability to mediate transcriptional activation.
Yeast genetics has proven to be very useful in identifying potential coactivator genes. For example, the SRB genes were isolated as suppressors of truncations in the conserved carboxy-terminal domain of RNA polymerase II (33, 55) . These gene products copurify in a complex, called the mediator, that can bind activators (25) and has coactivator activity (25, 32) . This mediator complex and the core RNA polymerase II subunits form the RNA polymerase II holoenzyme, which can support activated transcription (32, 34) . The products of the SWI1, SWI2/SNF2, SWI3, SNF5, and SNF6 genes, identified as positive regulators of SUC2 and HO transcription (39, 54) , are part of a subcomplex of the mediator/holoenzyme (57) that antagonizes histone repression in vivo and in vitro (7, 27) .
Other yeast coactivator gene candidates include ADA2, ADA3, and GCN5, isolated in a selection for mutants resistant to GAL4-VP16-mediated toxicity (4, 5, 38) . Mutations in these genes relieve toxicity by reducing the ability of the VP16 activation domain to activate transcription without altering the levels of GAL4-VP16 in cells. Moreover, ada2, ada3, and gcn5 mutants all have similar phenotypes, including slow growth on minimal medium, temperature sensitivity, and a reduced ability to support activation by certain activation domains in vivo and in vitro (4, 38, 40) . ADA2, ADA3, and GCN5 form a complex when translated in vitro (30) , and they cofractionate from yeast extracts (53) . The fact that double mutants with mutations in these genes have phenotypes indistinguishable from those of single mutants also supports the model that ADA2, ADA3, and GCN5 function together in a complex (38) . ADA2 can bind VP16 and GCN4 activation domains (2, 52) and may be is necessary for a TBP-VP16 interaction in yeast extracts (2) .
Another set of yeast genes important for proper transcriptional regulation and promoter selection, the SPT genes, were identified as suppressors of Ty insertions in yeast promoters (59) . These genes may be grouped into two classes, those that affect transcription via chromatin and those that affect transcription in a chromatin-independent manner (58). The latter class includes SPT15, which encodes TBP (12, 22) , as well as SPT3, SPT7, and SPT8 (12) . Genetic evidence suggests that SPT3, SPT7, and SPT8 may act as a complex with TBP, and SPT3 can be coimmunoprecipitated with TBP (10, 11, 14) . Strains harboring spt3, spt7, spt8, or spt15 mutations show reduced expression of the Ty element, reduced expression of other yeast genes, and an alteration in promoter selection at Ty loci (58) .
Here we report the cloning and initial characterization of ADA5. The phenotypes of ada5 mutants and of double mutants suggest that ADA5 operates in the same pathway as the other ADA genes (ADA2, ADA3, and GCN5). Moreover, ADA5 cofractionates with ADA3 in yeast extracts. ADA5 is identical to SPT20 (45) and is the only ada gene to date to display Spt Ϫ phenotypes. We present a speculative pathway of interaction of ADA5 and the other ADA proteins in connecting activators to basal factors at promoters.
MATERIALS AND METHODS
Yeast strains and manipulations. All yeast strains are derivatives of BWG1-7a (MATa ade1-100 ura3-52 leu2-3,112 his4-519) (20) , BP1 (MATa ade1-100 ura3-52 leu2-3,112 his4-519 gal4::HIS4), or PSy316 (MAT␣ ura3-52 leu2-3,112 his3⌬200 lys2) (4) . GMy37p (MATa ura3-52 leu2 his4 gal4::HIS4 ada5-1) was isolated as a strain resistant to GAL4-VP16 toxicity (38) . Fy strains, L881, and YSMR strains were gifts from Fred Winston.
Yeast transformations were performed by the lithium acetate method (16) . Tetrad analysis and other yeast manipulations were done according to standard techniques (21) . Slow-growth phenotypes of ada mutants were assayed on synthetic dextrose minimal medium supplemented with only the necessary amino acids and adenine (Difco). Otherwise, strains were grown on synthetic complete (SC) medium containing all amino acids except those needed for plasmid selection.
ADA5 cloning and plasmids. To clone the wild-type ADA5 gene, GMy37p, the ada5-1 mutant, was transformed with a yeast genomic library (55) and colonies that grew as well as the wild type were selected. From these, a clone, p3,1 with an 8.5-kb insert that restored wild-type growth and sensitivity to GAL4-VP16 toxicity was isolated. p3,1 was subjected to partial digestion with Sau3AI, and 1-to 3-kb fragments were isolated and ligated into the BamHI site of pRS316 (51) to create a subgenomic library. GMy37p was transformed with this subgenomic library, and colonies that grew as well as the wild type were again selected. Two truncated subclones were isolated for further study: pL1B1 (with a 2.2-kb insert), which partially complements the slow-growth phenotype of GMy37p, and pL1G1 (with a 1.8-kb insert), which fully complements the slow-growth phenotype. Both subclones complement the toxicity resistance phenotype of ada5-1. Sequence analysis (see below) revealed that pL1B1 is lacking the upstream sequences of ADA5 as well as the region encoding the first 10 amino acids. Presumably, the remaining region of ADA5 is expressed from a cryptic promoter in the vector and an internal methionine in the ADA5 coding sequence. pL1G1 is a C-terminal ADA5 truncation, containing approximately 500 bp of upstream sequences and 1,368 bp of the coding region, which encodes residues 1 to 456.
pRS316-ADA5, a subclone with the entire ADA5 coding region, was created in several stages. The BstXI site in pRS316 (51) was destroyed by digesting, blunting with T4 polymerase, and ligating to create pRS316-BstXI. A 1.9-kb EcoRI fragment containing the sequences encoding the first 437 amino acids of ADA5 as well as the upstream sequences was cloned into the EcoRI site to create pRS316-ADA5 437a and pRS316-ADA5 437b . pRS316-ADA5 437a is oriented such that the BstXI site at the 5Ј end of ADA5 is proximal to the SacI site in the polylinker. pRS316-ADA5 437b is in the other orientation. A 1.9-kb BstXI-HindIII fragment from pL1B1 was cloned into the BstXI-HindIII sites of pRS316-ADA5 437a to create pRS316-ADA5. A 2.6-kb XhoI-NotI fragment from pRS316-ADA5 was cloned into pRS315 (51) cut with XhoI and NotI to create pRS315-ADA5.
The ADA5 coding sequence was amplified by PCR (Perkin-Elmer) with primers ADA5N (CCCGGGAGATCTGCGCCGCAATGAGTGCCAATAGCCCG ACAGG) and ADA5C (CCCGGGGGATCCGCGGCCGCCTAAGATCTTGA CATTGTAGTAGAAGAGGGCG). The resulting fragment was digested with NotI and cloned into the NotI site of pDB20L (4) to form pDB20L-ADA5. pBluescript-ADA5 was generated by cloning a 2.2-kb BamHI HindIII fragment from pL1B1 into Bluescript KSϩ (Stratagene) cut with BamHI and HindIII.
To show that the cloned gene corresponds to the ada5-1 mutation, pRS306-ADA5 was generated by cloning a 1.8-kb XbaI fragment from p3,1 into the XbaI site of a version of the URA3 integrating vector pRS306 (51) with the EcoRI site destroyed. pRS306-ADA5 was cut with EcoRI (a unique site in the 1.8-kb insert) and transformed into PSy316. A colony with an integration at the cloned locus was mated to GMy37p, and the resulting diploid was sporulated. In each of five tetrads dissected, two spores gave rise to slowly growing Ura Ϫ colonies and two spores gave rise to Ura ϩ colonies with wild-type growth, showing that the cloned gene maps to the ada5-1 mutant locus.
ADA5 sequencing. All sequencing was done by using the Sequenase kit (U.S. Biochemicals). A deletion series from the NotI site of pL1B1 was generated with exonucleases III and VII and sequenced with the Ϫ20 primer. The sequence of the other strand was obtained by using the T3 primer to sequence a second deletion series from the KpnI site of pL1B1 or from sequence-specific primers. Since pL1B1 does not fully complement the ada5-1 mutant and since the largest open reading frame on pL1B1 was found to be open at the 5Ј end, the other subclone, pL1G1, was partially sequenced. The sequence obtained with the Ϫ20 primer in pL1G1 showed that it is lacking sequences after residue 1368 in the putative ADA5 open reading frame and thus encodes a C-terminal truncation of ADA5. By using a sequence-specific primer, it was determined that the incomplete open reading frame identified in pL1B1 continues for an additional 30 bp in pL1G1. To confirm that the ADA5 open reading frame is continuous across the truncation junctions present in pL1B1 and pL1G1, the full-length ADA5 genomic clone (p3,1) was used to sequence across these junctions with sequencespecific primers.
ADA5 deletion plasmid and strains. The ADA5 deletion plasmid was created in several steps. A 550-bp XhoI-blunted BstXI fragment from pL1G1 containing sequence encoding the first 12 amino acids of ADA5 and 5Ј flanking sequence was cloned into the XhoI and EcoRV sites of pBluescript KSϩ (Stratagene) to form pBluescript-A5BstX. Next, a 2.4-kb BamHI-BglII fragment containing the hisG URA3 cassette from pNKY51 (1) was cloned into the BamHI site of pBluescript-A5BstX. A clone, pADA5nko, was chosen such that the reformed BamHI site was distal to the ADA5 5Ј sequence. Finally, pBluescript-ADA5 was cut with DraIII, ligated to a NotI linker (New England Biolabs), and cut with NotI and BstYI. The 400-bp BstYI-NotI fragment containing sequences encoding the C-terminal 136 amino acids and 3Ј flanking sequence was cloned into the BamHI-NotI site of pADA5nko to form pADA5KO. This plasmid will delete the coding sequence for 437 amino acids from the N terminus of ADA5, which should produce a null phenotype.
ADA5 deletion strains (⌬ada5 strains) were generated by transforming yeast cells with pADA5KO cut with XhoI-NotI. Slowly growing Ura ϩ transformants were tested for resistance to GAL4-VP16 and mated to previously characterized ada5 mutant strains of the opposite mating type when these strains were available. Strains that were resistant to GAL4-VP16 were grown on 5-fluoroorotic acid to select for strains that had looped out the URA3 sequence. Ura Ϫ derivatives were transformed with pRS316-ADA5 to confirm that wild-type growth and sensitivity to GAL4-VP16 were restored by the ADA5 clone. In this manner, the Ura ϩ and Ura Ϫ deletion strains GMy29 and GMy30 were generated in the parent strain BWG1-7a, GMy31 and GMy32 were generated in BP1, and GMy33 and GMy34 were generated in PSy316.
The ⌬ada2 ⌬ada5 and ⌬ada3 ⌬ada5 double deletion strains were generated in the following manner. GMy30 containing the plasmid pDB20L-ADA5 was transformed with pADA2KO (4) cut with BamHI and XhoI or with pADA3KO cut with PvuII and BamHI (38) . ada2 or ada3 deletion strains were identified by mating slowly growing transformants to ⌬ada2 or ⌬ada3 strains. Strains that failed to complement the cognate ⌬ada strain were grown on 5-fluoroorotic acid to select strains that had looped out the URA3 sequence.
The resulting Ura Ϫ derivatives were grown on yeast extract-peptone-dextrose (YPD) plates and replica plated to identify strains that had lost the LEU2 plasmid containing the ADA5 clone. GMy36 (BWG1-7a ⌬ada2 ⌬ada5) can be restored to wild-type growth only by transformation with both the ADA5 (pRS315-ADA5) and ADA2 (pNS3.8 [4] ) clones, confirming that it is a double mutant. Similarly, GMy38 (BWG1-7a ⌬ada3 ⌬ada5) was confirmed by transformation with the ADA5 and ADA3 (pADA3HHV [40] ) clones.
ADA5 expression, antisera, and Western blot (immunoblot) analysis. pET15b-ADA5, an ADA5 expression vector, was created by exploiting the single BamHI site in pL1B1, created when the 2.2-kb Sau3AI fragment from p3,1 was cloned into the BamHI site of pRS316. This BamHI site, derived from the Sau3AI site at position 28 in the ADA5 coding sequence, is in frame with the BamHI-site of pET15b (Novagen), a vector that fuses six histidine residues at the N termini of expressed proteins. pL1B1 was digested with DraIII, ligated with a BamHI linker (New England Biolabs), and then digested with BamHI. The resulting 2.2-kb fragment was cloned into the BamHI site of pET15b (Novagen) to form pET15b-ADA5. In the bacterial strain BL21(DE3) (Novagen), this plasmid produces insoluble ADA5, which was purified in urea on a nickel column (Qiagen).
Polyclonal rabbit ADA3 or ADA5 antiserum was generated by standard procedures (23) . For ADA5, two rabbits were immunized with lyophilized acrylamide slices containing 400 g of ADA5 resuspended in saline followed by six boosts, three containing 200 g of ADA5 and three containing 100 g. Immunoglobulin G was purified from serum on a protein A column (23) . Antiserum to ADA3 was generated by injecting rabbits six times with 0.5 mg of a fragment of ADA3, ADA3(580-702), in RIBI adjuvant (RIBI ImmunoChem Research, Inc.). The expression and purification of ADA3(580-702) have been previously described (30) . The antiserum was purified by binding and eluting from immunoblots of ADA3(580-702) (23) .
Western blotting was performed as follows. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on samples run in the absence of a reducing agent to eliminate a contaminating keratin band that comigrates with ADA5. Proteins were transferred to polyvinylidene difluoride (DuPont) by using a Milliblot graphite electroblotter (Millipore), and filters were probed by standard techniques (23) with affinity-purified anti-ADA3 serum or purified anti-ADA5 immunoglobulin G. Proteins were visualized by using a horseradish peroxidase-conjugated secondary antibody with the ECL system (Amersham).
Fractionation and immunoprecipitation of yeast extracts. BWG1-7a was grown in 5 liters of YPD to an optical density at 600 nm of approximately 4. GMy30 was grown in 10 liters of YPD to an optical density of approximately 2. This yielded a wet weight of 35 g of cells each. Preparation of yeast whole-cell extract and fractionation with a Bio-Rex 70 (Bio-Rad Laboratories) column were performed as described elsewhere (49, 55) with the following modifications. Bio-Rex 70 columns (1.5 by 7 cm) were used, and protein was eluted from the columns successively with buffer A (49) containing 250 mM, 600 mM, and 1.2 M potassium acetate.
Immunoprecipitation experiments were performed with the 600 mM elution fractions from the Bio-Rex 70 columns. Antibodies from crude preimmune serum and from crude anti-ADA5 serum were cross-linked to protein A-Sepharose beads (Sigma) as previously described (6, 23) . Comparison of antibodies eluted from the protein A beads before and after cross-linking by boiling, PAGE, and staining with Coomassie brilliant blue demonstrated that equal amounts of antibody were cross-linked from both sera. The beads were washed several times with 100 mM glycine (pH 2.5) to remove un-cross-linked antibody and then washed several times and equilibrated in IP buffer (6) with 0.1 M potassium acetate. Immunoprecipitations were performed as described previously (6) . Briefly, 100 g of the 600 mM fraction from BWG1-7a or 150 g of the 600 mM fraction from GMy30 was precleared with protein A-Sepharose beads and then incubated with antibody-cross-linked beads by rotation at 4ЊC for 3 h. The beads were sedimented and washed four times with 1 ml of IP buffer with 0.1 M potassium acetate. Bound proteins were then eluted from the beads by two successive elutions with 12 l of 100 mM glycine (pH 2.5). The eluates were pooled and analyzed by Western blotting.
GST-VP16 precipitations. The ADA5 in vitro transcription-translation plasmid pCITE2b-ADA5 was generated by cloning the 2.2-kb BamHI fragment containing the ADA5 coding sequence and 3Ј sequence from pET15b-ADA5 into the BamHI site of pCITE2b (Novagen). In vitro translations were performed as previously described (30) .
Precipitation experiments were performed by loading 10 g of glutathione S-transferase (GST)-VP16(413-490), GST-VP16FA442,FA475, or GST-VP16⌬ (413-456) on 10 l of glutathione-Sepharose beads (Pharmacia) that were preblocked in Escherichia coli extract. Ten microliters of in vitro-translated ADA5 and 200 l of S300-1%T buffer (20 mM HEPES [N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid] [pH 7.6], 300 mM potassium acetate, 25 mM magnesium acetate, 1% Triton X-100, 20% glycerol) plus 1 mg of E. coli extract per ml were added to the GST-VP16 beads and incubated for 1 h at 4ЊC. Samples were washed four times with 1 ml of S300-1%T buffer, eluted from the beads with 20 mM reduced glutathione (Sigma) in S300 buffer, and electrophoresed on an SDS-polyacrylamide gel. The gel was dried and exposed on XAR film (Kodak). GST-VP16 and GST-VP16⌬ expression constructs and purification techniques were described previously (37) . GST-VP16FA442,FA475 was made by cloning a BamHI-SphI fragment from pMSVP16FA442/FA475 (42) into the BamHI and SphI sites of pGVP (the GST-VP16 expression plasmid [37] ).
Gel shifts and ␤-galactosidase assays. ␤-Galactosidase assays were carried out on glass bead yeast extracts (46) . The activity of ␤-galactosidase was normalized to the level of total protein. Gel shift analysis was performed as previously described (4) .
Nucleotide sequence accession number. The GenBank accession number for the ADA5 sequence is U43153.
RESULTS
Properties of the ada5-1 mutant. A screen for relief of GAL4-VP16-induced toxicity (4) identified multiple alleles of ADA2, ADA3, and GCN5 and a single allele of ADA5, ada5-1 (38) . The ada5-1 mutant grows slowly on rich as well as minimal media. This is in contrast to the other ada mutants, which have a pronounced slow-growth phenotype only on minimal media (38) . This slow-growth phenotype segregated 2 slow:2 wild type in six complete tetrads and cosegregated with resistance to GAL4-VP16 (data not shown).
ADA2, ADA3, and GCN5 mutants survive GAL4-VP16 toxicity by reducing the ability of GAL4-VP16 to activate transcription, rather than by reducing the level of the toxic protein (4, 38, 40) . Since GAL4-VP16 is toxic to wild-type cells, we assayed levels of a less toxic derivative, GAL4-VP16FA, expressed on a low-copy-number plasmid also under control of the ADH1 promoter, by gel shift (4). Compared with that in the wild type, less of the GAL4-VP16 specific complex was found in the ada5 mutant (data not shown). Thus, unlike the other ADA gene products studied to date, it is possible that cells missing ADA5 escape because of a toxicity reduced level of GAL4-VP16.
Cloning, mapping, and sequencing of ADA5. ADA5 was cloned by complementation of the slow-growth phenotype of the ada5-1 mutant (see Materials and Methods). The ADA5 clone has the ability to restore wild-type growth and sensitivity to GAL4-VP16 to the ada5 mutant strain (data not shown). To confirm that the clone indeed corresponds to the ADA5 gene, we directed integration of URA3 in plasmid pRS306-ADA5 to the cloned locus in a wild-type strain (see Materials and Methods). This strain was mated to the ada5-1 strain, the diploid was sporulated, and tetrads were dissected. In all five tetrads, two spores grew slowly and were Ura Ϫ and two spores grew normally and were Ura ϩ , showing linkage between the clone and the ada5-1 mutation.
In order to map ADA5 to the yeast physical map, a fragment from the gene was radiolabeled and hybridized to a phage grid representing over 90% of the yeast genome (43) . Two overlapping clones were identified, showing that ADA5 maps to the right arm of chromosome XV.
ADA5 was further subcloned and sequenced (see Materials and Methods). The gene encodes a novel protein with 604 amino acids and a predicted molecular mass of 68 kDa. The ADA5 protein contains two glutamine-rich regions, several Ser-Thr-rich regions, a proline-rich region, an acidic region, and a basic region (Fig. 1) . As a final confirmation that the open reading frame we identified corresponds to ADA5, the open reading frame was amplified by PCR and placed under VOL. 16, 1996 ADA5/SPT20 LINKS YEAST ADA AND SPT GENES 3199 the control of the ADH1 promoter (see Materials and Methods). This plasmid complements the ada5-1 mutation as well as the genomic clone. Characterization of ADA5 deletion mutants. ada5 deletion mutants (⌬ada5 mutants) were constructed by homologous recombination as described in Materials and Methods. The deletion mutant is viable but grows more slowly than the ada5-1 mutant (Fig. 2 ) and more slowly than ada2, ada3, or gcn5 deletion mutants (not shown). Like other ada mutants, the ada5 mutant is temperature sensitive for growth and completely resistant to GAL4-VP16. However, unlike the other ada mutants, the ada5 mutant is auxotrophic for inositol (data not shown).
Analysis of an amino-terminal fragment of ADA5 for complementation of cell growth and toxicity by GAL4-VP16. In the process of subcloning ADA5, we discovered that a portion of the ADA5 coding sequence could be deleted without loss, or with only partial loss, of the ability to complement an ada5 mutant strain (see Materials and Methods). As shown in Fig. 3A and B, ADA5 437 , encoding the first 437 amino acids of ADA5, can complement a ⌬ada5 strain for growth on rich medium and partially complement for growth on minimal medium. However, ADA5 437 strains remain resistant to GAL4-VP16 (Fig. 3C) . These findings show that the ADA fragment containing amino acids 1 to 437 complements the growth phenotype but does not restore the toxicity of GAL4-VP16. It is thus possible that the deletion in ADA5 separates two functions of the gene product. Alternatively, the observed properties of the deletion may result from a quantitative reduction in ADA5 activity.
In vivo activation defects of ada5 strains. The lower levels of GAL4-VP16FA in ada5 mutants may indicate that ADA5 is required for activation at the ADH1 promoter. To determine whether the ADH1 promoter or other yeast promoters require ADA5 for activation, we introduced ␤-galactosidase reporter plasmids under the control of eight different yeast UAS sequences into the wild-type, the ada5-1 mutant, and the ada5 deletion strains.
The activities of these reporters, as measured by ␤-galactosidase assays, are shown in Table 1 . The activities of the HO and INO1 promoters are the most drastically reduced. The activities of the GCN4-responsive HIS66 and 14x2 promoters, which are known to require ADA2/ADA3/GCN5 (4, 38, 40) , are also severely reduced in the ada5 mutant and deletion strains. The CYC1 UAS1 promoter, which is known not to require ADA2, ADA3, and GCN5, is reduced 3-fold in the ada5-1 mutant and 10-fold in the ada5 deletion strain. Interestingly, FIG. 2 . The ada5 deletion mutant strain grows more slowly than the ada5-1 mutant strain. GMy30 (⌬ada5), GMy37p (ada5-1), and BWG1-7a (isogenic wildtype [WT] strain) were streaked on rich (YPD) medium. Growth was scored after 2 days (A) and 3 days (B).
FIG. 3.
The sequence encoding the first 437 amino acids of ADA5 is sufficient to complement the slow-growth phenotype of ⌬ada5 mutants on rich medium but only partially complements on minimal medium. (A) GMy30, a ⌬ada5 mutant, was transformed with the full-length ADA5 clone, the ADA5 437 fragment (containing sequence encoding the first 437 amino acids of ADA5), or a vector control. Transformants were either restreaked on SC medium and scored after 2 days (A) or restreaked on synthetic dextrose medium and scored after 3 days (B). (C) ADA5 437 does not restore sensitivity to GAL4-VP16 to an ada5 deletion strain. GMy30 complemented by full-length ADA5 or ADA5 437 was transformed with pSB201, a 2m plasmid expressing GAL4-VP16 from the ADH1 promoter, or a vector control and plated on SC medium. Transformation plates were scored for growth after 3 days. the activities of the CYC1 UAS2, ADH1, and GAL1-10 promoters, which are not affected by ada2 mutations, are reduced only three-to fivefold in the ada5 deletion strain.
In summary, the ada5 deletion strain has a broad defect in transcription affecting all of the promoters tested. However, there may be a relationship between the spectra of effects in ada5 and ada2 mutants. In particular, the SD5, ADH1, and UAS2 promoters, which are the least affected in the ada5 mutants, are not affected at all in ada2 mutants (4, 40) . The reduction in activation of the ADH1 and INO1 promoters explains the novel phenotypes of ada5 mutants, i.e., a small reduction in GAL4-VP16 levels and inositol auxotrophy.
Double mutants with mutations in ADA5 and other ADA genes. The above-described findings raise the question of whether ADA5 functions in the same pathway as the other ADA genes. To begin to address this issue, we constructed double mutants carrying ada5 and ada2 or ada3 mutations (see Materials and Methods). We found that both ⌬ada2 ⌬ada5 and ⌬ada3 ⌬ada5 double deletion mutants are viable and grow no more slowly than ⌬ada5 single mutants (Fig. 4 and data not shown). These findings suggest that ADA5 may operate in the same pathway as the other ADA genes. In Discussion, we speculate on how ADA5 may operate in the same pathway as the other ADA genes yet have a more general function in transcription.
Specific binding of ADA5 to functional VP16 activation domains. We began a biochemical analysis of ADA5 by studying whether the protein bound to the activation domain of VP16. ADA5 was translated in vitro, radiolabeled, and added to glutathione-Sepharose beads coupled to GST-VP16. After extensive washing, the GST fusion was eluted from the beads with glutathione, and the eluent was electrophoresed on an SDSpolyacrylamide gel. Autoradiography of the gel indicated a band the size of the onput ADA5 protein, showing that the protein bound to the beads (Fig. 5) . Two mutant VP16 proteins were also fused to GST and used as controls. The first contained a deletion of residues 457 to 490 of VP16, leaving intact residues 413 to 456. This VP16 derivative shows greatly reduced activity in yeast cells (52) . The second mutation changes only the Phe residues at positions 442 and 475 to Ala. This mutant shows a large reduction in activity in mammalian cells (42) . In both cases, the mutations abolished the binding of ADA5. Following autoradiography, Coomassie staining of the gel showed that the same amounts of all three GST fusion proteins were bound to and eluted from the beads (data not shown). This experiment shows that ADA5 binds to the activation domain of VP16 but not to nonfunctional mutant domains. Models for ADA5 function must take into account this activity.
Cofractionation of ADA5 and ADA3. The genetic and biochemical findings summarized in the introduction indicate that ADA2, ADA3, and GCN5 function together in a complex (30, 38) . Because the growth phenotypes of ⌬ada5 ⌬ada2 and ⌬ada5 ⌬ada3 double mutants suggest that ADA5 may be acting in the same pathway as ADA2, ADA3, and GCN5, we examined whether ADA5 copurifies with a member of the ADA complex, ADA3.
The first step in purification of the ADA complex (which will be described in detail elsewhere) was to chromatograph a yeast whole-cell extract on a Bio-Rex 70 cation-exchange column. We assayed the flowthrough and three salt elution fractions from this column by Western blot analysis for ADA5 and ADA3. As shown in Fig. 6A, ADA3 and ADA5 eluted primarily in the 600 and 1,200 mM potassium acetate fractions in very similar proportions. ADA2 and GCN5 also elute in the 600 and 1,200 mM fractions with a profile identical to those of ADA3 and ADA5 (53) . As a control, an extract from a ⌬ada5   FIG. 4 . ⌬ada3 ⌬ada5 double deletion mutants grow as well as ⌬ada5 deletion mutants. GMy38, a ⌬ada5 ⌬ada3 double deletion mutant, was transformed with all pairwise combinations of pRS315-ADA5 or pRS315 (a LEU2 vector) and pADA3HHV or pRS316 (a URA3 vector). Transformants indicated by plasmidborne genes were restreaked on dropout medium and scored after 3 days. Note that the ⌬ada3 ⌬ada5 transformant (pRS316 pRS315) grows comparably to the ⌬ada5 transformant (pADA3 pRS315). Growth of the ⌬ada3 transformant (pRS316 pADA5) is intermediate between those of the double deletion strain and the wild type (pADA3 pADA5). ) and ada5-1 and ⌬ada5 mutants were transformed with the following ␤-galactosidase reporter plasmids: pLG312⌬AluXho, which contains the CYC1 UAS1 (19); p265UP1, which contains the CYC1 UAS2 (13); pHIS66, which contains the HIS4 UAS (26); p14x2, which contains two synthetic GCN4 binding sites (26) ; pCP8 (gift of C. Peterson), which contains the HO URS1 (position Ϫ1516 to Ϫ901); pINO1 (50); and pLGSD5, which contains the GAL1-10 promoter, and pCP0, which contain the ADH1 promoter (47). ␤-Galactosidase gene activities are means of results from three assays differing by less than 20% and are normalized to the level of total protein. The activity of pLGSD5 was measured after induction with galactose, and the activity of the INO1 reporter was assayed after 5 h of induction in inositol-free medium (50) .
b ND, not determined.
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ strain was also fractionated, clearly showing that the indicated band is ADA5 because it was absent in the mutant. To obtain more direct evidence for the association between ADA3 and ADA5, the 600 mM fraction from the Bio-Rex column was immunoprecipitated with anti-ADA5 or preimmune serum. As a control, this immunoprecipitation was also performed with the 600 mM fraction of the ada5 deletion extract. Western blot analysis of the precipitates with anti-ADA3 (Fig. 6B) shows that ADA3 was precipitated with anti-ADA5 but not preimmune serum. Moreover, ADA3 was not precipitated from the extract missing ADA5. (Note that the lanes labeled starting material were loaded with the same amount of total protein.) The observation that less ADA3 is detected in the ⌬ada5 extract may indicate that less ADA3 is present in the absence of ADA5. We conclude from these findings that ADA5 and ADA3 are physically bound to one another in a complex in yeast extracts.
Identification of ADA5 as SPT20. By comparing sequences, it was determined that ADA5 is identical to SPT20 (45), a newly isolated SPT gene in the TBP class (12, 22) . spt20 mutants, like the other spt mutants of this class, have pleiotropic mating, growth, and sporulation defects. Furthermore, transcription of Ty1 and other yeast genes is compromised. Thus, unlike the other ada mutants (29, 45) , ada5 mutants also have an Spt Ϫ phenotype.
Ada ؊ phenotype in two SPT15 (TBP) mutants. We examined spt3, -7, -8, -15, and -20 mutants (all in the TBP class), as well as spt5, -6, and -4 mutants, for resistance to GAL4-VP16-mediated toxicity (the Ada Ϫ phenotype). As shown in Table 2 , the spt20 mutant (as expected) and the spt7 mutant were completely resistant to GAL4-VP16. Like ada5 mutants, spt7 mutants show reduced activation of the ADH1 promoter (44), and we cannot rule out the possibility that this is the basis of the resistance. Interestingly, other spt mutants, including spt3 and spt8 mutants in the TBP class, were sensitive to GAL4-VP16. Roberts and Winston have found that spt7 and spt20 have very similar phenotypes, including inositol auxotrophy and slow growth on rich media, that are not shared by spt8 or spt3 (45) .
Two spt15 (TBP) alleles, spt15-21 and spt15-122, caused partial resistance to GAL4-VP16 (Table 2) . Interestingly, spt15-21, the spt15 allele causing the most resistance, also causes inositol auxotrophy (45) . Because of the possible pleiotropic nature of spt15 mutations, resistance to GAL4-VP16 could be due to reduced levels of the toxic chimera in the mutant strains. To address this issue, levels of GAL4-VP16 in both the spt15-21 and spt15-122 strains were determined by gel shift analysis (Fig. 7) . Levels in the spt15-122 strain were indistinguishable from those in the wild type, while levels in the spt15-21 strain were somewhat higher than those in the wild type. In addition, for reasons that are not clear, the form of the chimera which corresponds to full length (i.e., the unproteolytically cleaved form) is favored in the spt15-21 extract. Thus, the Ada Ϫ phenotype of these mutants is not due to a reduction in levels of GAL4-VP16. These findings provide the first genetic clue that the ADA functional pathway includes a basal factor, TBP, and they are consistent with in vitro findings (2) (see Discussion).
DISCUSSION
Here we report the cloning and initial characterization of ADA5, a novel gene selected by resistance to GAL4-VP16-mediated toxicity. Strains with mutations in ADA5 display some phenotypes that are distinct from those of strains with mutations in the previously described genes ADA2, ADA3, and GCN5, which arose from the same selection. First, ⌬ada5 strains show reduced levels of GAL4-VP16, unlike ada2, ada3, or gcn5 deletion strains. Second, ada5 mutants grow more slowly on rich and minimal media than other ada mutants. Third, ada5 strains are inositol auxotrophs and have Spt Ϫ phenotypes. Fourth, promoters that function independently of ADA2, such as UAS1 and ADH1, are dependent on ADA5. The effects on the ADH1 promoter account for the reduction in GAL4-VP16 levels. Although ADA5 appears to be distinct from the other ADA genes, some phenotypes suggest they may all function in the same pathway. The activators that require ADA2 for activation are also dependent on ADA5. GCN4-mediated activation, which is highly ADA2 dependent (40) , is also ADA5 dependent. HAP4-and GAL4-mediated activation, which are only slightly ADA2 dependent (40) , are less ADA5 dependent than most of the other activators tested (Table 1 , activities of UAS2 and SD5). Moreover, double mutants with mutations in ada5 and either ada2 or ada3 have growth phenotypes no more severe than those of ada5 single mutants. If the ADA2 complex and ADA5 work through different activation pathways, then we would expect these double mutants to have a more severe growth defect than either of the single mutants. These genetic data suggest that ADA5 and ADA2-ADA3-GCN5 function in the same pathway of transcriptional activation in cells.
Biochemical studies provide direct evidence that ADA5 is a part of the ADA complex. Fractionation of a yeast extract on a Bio-Rex 70 column shows cofractionation of ADA5 and ADA3. Further, immunoprecipitation of ADA5 coprecipitates ADA3. If an extract from a ⌬ada5 strain is used as a control in this experiment, no ADA3 is precipitated.
ADA5 as an SPT gene. The more general effects of ada5 mutations on transcription are underscored by its identity with SPT20 (45). It is intriguing that this gene influences promoter selection when two promoters are in competition, as well as transcriptional activation (as do other ADA genes). The identity of ADA5 and SPT20 prompted us to examine a panel of SPT mutants for the Ada Ϫ phenotype, i.e., resistance to toxicity by overexpressed GAL4-VP16. spt7 mutants were also resistant, and, like spt20 mutants, their resistance was complete. Other spt mutants, including spt3 and spt8 mutants, in the TBP phenotypic class were sensitive. These findings suggest the possibility that SPT7 and SPT20 function together in the transcription process, a surmise also indicated by the findings of Roberts and Winston (45) .
SPT15 (TBP) mutants show resistance to GAL4-VP16. We also observed that two spt15 mutants were partially resistant to GAL4-VP16. This result provided the first possible genetic link between the ADA pathway of transcriptional activation and a basal factor, namely, TBP. To further characterize this finding, we showed that the resistance of these spt15 mutants did not arise from a reduction in levels of the toxic chimera. The similarity in phenotypes between spt7, ada5, and spt15 alleles, including inositol auxotrophy and toxicity resistance, suggests that the target of the ADA activation pathway could be TBP. Our genetic findings are consistent with the earlier biochemical findings of Barlev et al. (2) , who also proposed that ADA2-ADA3-GCN5 may contact the basal machinery by binding to TBP. They found that TBP in yeast extracts from a wild-type strain bound to a VP16 column, while TBP from ada2 mutant extracts did not.
We suggest a pathway which leads from the activation domain of transcriptional activators to a complex, ADA2-ADA3-GCN5-ADA5, and to TBP. Several findings are consistent with this model. First, ADA2 has been shown to bind to the activation domains of VP16 (2, 52), GCN4 (2), and ADR1 (8) . We show here that ADA5 binds to VP16 and that amino acid substitutions in VP16 can abolish this binding. Second, ada5   FIG. 7 . Levels of GAL4-VP16 are not reduced in spt15-21 or spt15-122 mutants. The indicated SPT ϩ or spt15 strains were transformed with pGAL4-VP16FA a/c, an ARS-CEN plasmid that expresses GAL4-VP16FA from the ADH1 promoter. Fifty-microgram portions of whole-cell protein extracts were mixed with a radiolabeled GAL4 oligonucleotide probe. Lane 1, which utilized an extract from a strain without GAL4-VP16, shows complexes due to host proteins (host). GAL4-VP16 complexes are indicated (4).
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ (and spt7) mutations can affect promoter selection (i.e., the mutants have Spt Ϫ phenotypes), suggesting that TBP may be a target of the ADA complex. Third, mutations in SPT15 (TBP) can give rise to partial resistance to GAL4-VP16. This finding, along with the earlier biochemical data (2), also indicates that TBP might be the ultimate target of ADA-mediated activation.
How can ada5 mutants share some phenotypes with ada2, ada3, and gcn5 mutants yet exert a broader range of effects? We suggest the possibility that ADA5 (and possibly SPT7) retains a partial activity in the absence of ADA2, ADA3, and GCN5. This activity may suffice in ada2 mutants for transcription of ADH1, INO1, and perhaps other genes. Deletion of ADA5, in this model, would destroy all activity of the complex and give rise to a broader spectrum of phenotypes (i.e., Spt Ϫ , Ino Ϫ , and slower growth). In summary, we have presented the analysis of a novel gene, ADA5, that shares phenotypes of two broad classes of yeast genes affecting transcription, the ADA genes and the SPT genes. It will be interesting to see how this genetic connection between these different classes of factors reflects the physical arrangement of the coactivators at promoters.
